Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 3
1989 1
1993 2
1994 11
1995 8
1996 1
1997 8
1998 1
1999 4
2003 4
2004 1
2005 2
2006 2
2007 3
2008 3
2009 1
2011 1
2012 1
2014 2
2015 1
2016 3
2017 1
2018 4
2019 1
2020 3
2021 3
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

76 results
Results by year
Filters applied: . Clear all
Page 1
Conservative Treatment of Hemorrhoids: Results of an Observational Multicenter Study.
Zagriadskiĭ EA, Bogomazov AM, Golovko EB. Zagriadskiĭ EA, et al. Adv Ther. 2018 Nov;35(11):1979-1992. doi: 10.1007/s12325-018-0794-x. Epub 2018 Oct 1. Adv Ther. 2018. PMID: 30276625 Free PMC article.
INTRODUCTION: This study was conducted to determine the frequency of complaints in a cohort of patients with symptomatic hemorrhoidal disease (HD) treated with micronized purified flavonoid fraction (MPFF, Detralex). MPFF was selected for conservative treatment in this pop …
INTRODUCTION: This study was conducted to determine the frequency of complaints in a cohort of patients with symptomatic hemorrhoidal diseas …
[Detralex-phlebosclerosing treatment. Results of the national multicenter follow up programme VEIN ACT PROLONGED-C1].
Bogachev VI, Boldin BV, Turkin PI. Bogachev VI, et al. Angiol Sosud Khir. 2018;24(1):102-106. Angiol Sosud Khir. 2018. PMID: 29688201 Russian.
Presented herein are the results of the observational follow up study programme dedicated to the assessment of appropriate use of adjuvant therapy with Detralex while carrying out phlebosclerosing treatment in patients suffering from dilated intradermal veins (clinical cla …
Presented herein are the results of the observational follow up study programme dedicated to the assessment of appropriate use of adjuvant t …
[Clinical efficacy of Detralex in treatment of women with pelvic varicose veins].
Akhmetzianov RV, Bredikhin RA. Akhmetzianov RV, et al. Angiol Sosud Khir. 2018;24(2):93-99. Angiol Sosud Khir. 2018. PMID: 29924779 Russian.
Presented herein are the results of using Detralex in conservative treatment of women suffering from pelvic varicose veins. ...The obtained results make it possible to recommend routine prescription of Detralex to all women with detected pelvic varicose veins as one …
Presented herein are the results of using Detralex in conservative treatment of women suffering from pelvic varicose veins. ...The ob …
Treatment of rat adjuvant arthritis with flavonoid (Detralex), methotrexate, and their combination.
Rovenský J, Stancíková M, Rovenská E, Stvrtina S, Stvrtinová V, Svík K. Rovenský J, et al. Ann N Y Acad Sci. 2009 Sep;1173:798-804. doi: 10.1111/j.1749-6632.2009.04618.x. Ann N Y Acad Sci. 2009. PMID: 19758231
In this study treatment of adjuvant arthritis in rats with Detralex, methotrexate, and their combination were evaluated. Groups of rats with adjuvant arthritis were treated with methotrexate (0.6 mg/kg/week), Detralex (20 mg/kg/day), and their combination for 50 day …
In this study treatment of adjuvant arthritis in rats with Detralex, methotrexate, and their combination were evaluated. Groups of ra …
Effects of purified micronized flavonoid fraction (Detralex) on prophylactic treatment of adjuvant arthritis with methotrexate in rats.
Rovenský J, Svík K, Rovenská E, Stvrtinová V, Stancíková M. Rovenský J, et al. Isr Med Assoc J. 2008 May;10(5):377-80. Isr Med Assoc J. 2008. PMID: 18605365 Free article.
Interestingly, the arthritis-induced decrease of BMD in AA rats was significantly lower only in the group treated with the combination of Detralex+methotrexate. CONCLUSION: Detralex increased the therapeutic efficacy of methotrexate basal treatment in AA. We suggest …
Interestingly, the arthritis-induced decrease of BMD in AA rats was significantly lower only in the group treated with the combination of …
Oxidative DNA Damage in Blood of CVD Patients Taking Detralex.
Krzyściak W, Cierniak A, Kózka M, Kozieł J. Krzyściak W, et al. Open Cardiovasc Med J. 2011;5:179-87. doi: 10.2174/1874192401105010179. Epub 2011 Aug 1. Open Cardiovasc Med J. 2011. PMID: 21912579 Free PMC article.
The main goal of the work reported here was to determine the degree of oxidative/alkali-labile DNA damages in peripheral blood as well as in the blood stasis from varicose vein of (chronic venous disorder) CVD patients. Moreover, determination of the impact of Detralex usa …
The main goal of the work reported here was to determine the degree of oxidative/alkali-labile DNA damages in peripheral blood as well as in …
[Microcirculation end effect of detralex in patients with chronic venous insufficiency of the lower extremities].
Sirotin BZ, Zhmerenetskĭ KV. Sirotin BZ, et al. Angiol Sosud Khir. 2003;9(3):60-5. Angiol Sosud Khir. 2003. PMID: 14657934 Clinical Trial. Russian.
Fourteen patients with chronic venous insufficiency (CVI) of the lower extremities, class 0-4 according to the CEAP (1995) were examined for microcirculation (MC) and effect of detralex, using biomicroscopy of the conjunctival vessels and capillaroscopy of the nail matrix, …
Fourteen patients with chronic venous insufficiency (CVI) of the lower extremities, class 0-4 according to the CEAP (1995) were examined for …
[Pharmacological correction of total venous reflux in patients with varicose veins].
Khorev NG, Kuznetsova DV. Khorev NG, et al. Angiol Sosud Khir. 2021;27(1):84-89. doi: 10.33529/ANGIO2021110. Angiol Sosud Khir. 2021. PMID: 33825733 Russian.
The patients received a micronized purified flavonoid fraction (Detralex) in a daily dose of 1000 mg for 1 month. The venous function of the lower extremities was examined using venous photoplethysmography before and after the course of pharmacotherapy. ...In the overall s …
The patients received a micronized purified flavonoid fraction (Detralex) in a daily dose of 1000 mg for 1 month. The venous function …
[Analysis of surgical procedures on the vena saphena magna in the Czech Republic and an effect of Detralex during its stripping].
Veverková L, Kalac J, Jedlicka V, Wechsler J. Veverková L, et al. Rozhl Chir. 2005 Aug;84(8):410-2, 414-6. Rozhl Chir. 2005. PMID: 16218350 Clinical Trial. Czech.
The aim of this clinical study was to compare the degree of postoperative pain (VAS--10 cm, quality of life questionnaire CIVIQ and patient diary) between two groups of patients: patients treated with Detralex 14 days before and 14 days after the stripping of greater saphe …
The aim of this clinical study was to compare the degree of postoperative pain (VAS--10 cm, quality of life questionnaire CIVIQ and patient …
[The drug therapy of chronic venous insufficiency (a trial of the clinical use of the preparation Detralex)].
Iablokov EG, Bogachev VIu, Domoradskaia AI. Iablokov EG, et al. Ter Arkh. 1996;68(10):80-1. Ter Arkh. 1996. PMID: 9026954 Clinical Trial. Russian.
76 patients with severe venous insufficiency (CVI) entered the study. All the patients received 500 mg of Detralex twice daily for 2 months. The drug was well tolerated and relieved CVI symptoms in the majority of cases....
76 patients with severe venous insufficiency (CVI) entered the study. All the patients received 500 mg of Detralex twice daily for 2 …
76 results